SwitzerlandSwitzerland is home to a world-leading life-sciences ecosystem, anchored by Swissmedic and a highly sophisticated healthcare market. Taevas gives global brands the regulatory clarity, distributor access, and KOL networks needed to launch and scale with co
Select an industry to see regulatory pathways, services, and how Taevas supports your Switzerland market entry.
Swissmedic – Swiss Agency for Therapeutic Products
Switzerland's medical device market is among the most sophisticated in the world, governed by Swissmedic under the Medical Devices Ordinance (MepV), which aligns closely with the EU MDR framework. With a strong hospital infrastructure and a population that demands premium healthcare technology, Switzerland represents a high-value entry point for device manufacturers. Taevas maps your device classification, prepares your technical documentation, and connects you with Swiss distributors and clinical specialists.
Swissmedic classifies medical devices under the MepV into Classes I, IIa, IIb, and III based on risk. Taevas determines your classification and aligns your technical file with Swiss and EU MDR requirements.
Non-Swiss manufacturers must appoint a Swissmedic-registered Authorised Representative (CH-REP) before placing devices on the Swiss market. Taevas provides or arranges a qualified CH-REP to manage all regulatory correspondence.
Medical devices entering Switzerland require proper import documentation and alignment with Swiss customs authorities. Taevas coordinates logistics, import permits, and cold-chain requirements where applicable.
Swissmedic mandates ongoing post-market surveillance, vigilance reporting, and periodic safety update reports for all device classes. Taevas manages your PMS system and adverse event reporting obligations on a continuous basis.
Taevas combines deep Swissmedic regulatory expertise with an established network of Swiss distributors, KOLs, and healthcare professionals, giving life-sciences brands a proven, end-to-end partner for Switzerland market entry.
Our team has hands-on experience navigating Swissmedic authorisation processes for medical devices, pharmaceuticals, and biologics, ensuring your submissions are accurate, complete, and strategically timed.
Switzerland operates across German, French, and Italian language regions, each with distinct commercial dynamics. Taevas delivers localised strategies and communications tailored to all three linguistic markets.
Our pre-built regulatory templates, established FSVO and Swissmedic relationships, and in-country infrastructure reduce your Switzerland launch timeline by months compared to building in-house.
Taevas maintains active relationships with vetted Swiss distributors across hospital, pharmacy, health retail, and professional channels, enabling rapid commercial traction from day one.
We engage leading Swiss clinicians, pharmacists, and academic thought leaders to build the scientific credibility and professional endorsement your product needs to succeed in Switzerland's evidence-driven market.
From initial regulatory strategy through to post-launch sales support and pharmacovigilance, Taevas provides a single point of accountability for your entire Switzerland market entry journey.
Speak with a Taevas Switzerland specialist today and receive a tailored market entry assessment covering your regulatory pathway, timeline, and commercial strategy.